As2O3 enhances the anion transport activity of band 3 and the action is related with the C-terminal 16 residues of the protein

Journal of Drug Targeting

Volumn 13, Issue 4, 2005, Pages 235-243

  Fu, Guo Hui ^a   Wang, Yong ^b   Xi, Yu Hui ^c   Guo, Zhuo Wei ^c   Liu, Xiao Bin ^c   Bai, Shu Zhi ^c   Yang, Bao Feng ^c   Chen, Guo Qiang ^a,b  

^a SHANGHAI SECOND MEDICAL UNIVERSITY   (China)

^b SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

^c HARBIN MEDICAL UNIVERSITY   (China)

Author keywords

Anion transport activity; Apoptosis; Arsenic trioxide; Band 3; Transmembrane domain

Indexed keywords

ARSENIC TRIOXIDE; CASPASE 3; CHLORIDE ION; DIHYDRO 4,4' DIISOTHIOCYANO 2,2' STILBENEDISULFONIC ACID; ERYTHROCYTE BAND 3 PROTEIN; 4,4' DIISOTHIOCYANATOSTILBENE 2,2' DISULFONIC ACID; ANTINEOPLASTIC AGENT; ORGANOARSENIC DERIVATIVE; OXIDE;

ADULT; ANIMAL CELL; ANION TRANSPORT; APOPTOSIS; ARTICLE; CANCER PATIENT; CARBOXY TERMINAL SEQUENCE; CELL ISOLATION; CHLORIDE TRANSPORT; CONTROLLED STUDY; DISPLAY SYSTEM; DRUG SENSITIVITY; ENZYME ACTIVATION; ERYTHROCYTE; FEMALE; GENE DELETION; GENETIC TRANSFECTION; HELA CELL; HUMAN; HUMAN CELL; MALE; NONHUMAN; PHLEBOTOMY; PRIORITY JOURNAL; PROMYELOCYTIC LEUKEMIA; PROTEIN DOMAIN; PROTEIN EXPRESSION; YEAST CELL; BLOOD; DRUG EFFECT; GENETICS; IN VITRO STUDY; METABOLISM; YEAST;

4,4'-DIISOTHIOCYANOSTILBENE-2,2'-DISULFONIC ACID; ADULT; ANION EXCHANGE PROTEIN 1, ERYTHROCYTE; ANTINEOPLASTIC AGENTS; APOPTOSIS; ARSENICALS; ERYTHROCYTES; FEMALE; GENE DELETION; HELA CELLS; HUMANS; LEUKEMIA, PROMYELOCYTIC, ACUTE; MALE; OXIDES; TRANSFECTION; YEASTS;

EID: 23144454888     PISSN: 1061186X     EISSN: None     Source Type: Journal    
DOI: 10.1080/10611860500207060     Document Type: Article

References (43)

1. - exchangers by pH. JOP 2:171-175.
2. Bonifacino JS, Traub LM. 2003. Signals for sorting of transmembrane proteins to endosomes and lysosomes. Annu Rev Biochem 72:395-447.
3. Bordin L, Brunati AM, Donella-Deana A, Baggio B, Toninello A, Clari G. 2002. Band 3 is an anchor protein and a target for SHP-2 tyrosine phosphatase in human erythrocytes. Blood 100:276-282.
4. Cavigelli M, Li WW, Lin A, Su B, Yoshioka K, Karin M. 1996. The tumor promoter arsenite stimulates AP-1 activity by inhibiting a JNK phosphatase. EMBO J 15:6269-6279.
5. 3 induces NB4 cell apoptosis with downregulation of Bcl-2 expression and modulation of PML-RAR alpha/PML proteins. Blood 88:1052-1061.
6. 3 exerts dose-dependent dual effects on APL cells. Blood 89:3345-3353.
7. Davison K, Mann KK, Waxman S, Miller WH Jr. 2004. JNK activation is a mediator of arsenic trioxide-induced apoptosis in acute promyelocytic leukemia cells. Blood 103:3496-3502.
8. Fu G, Wang T, Yang B, Lv F, Shi C, Jiang X, Tian L, Yu W, Hamasaki N. 2004. Purification and characterization of the human erythrocyte band 3 protein C-terminal domain. Biochemistry 43:1633-1638.
9. Gallagher RE, Yeap BY, Bi W, Livak KJ, Beaubier N, Rao S, Bloomfield CD, Appelbaum FR, Tallman MS, Slack JL, Willman CL. 2003. Quantitative real-time RT-PCR analysis of PML-RAR alpha mRNA in acute promyelocytic leukemia: Assessment of prognostic significance in adult patients from intergroup protocol 0129. Blood 101:2521-2528.
10. Gilligan DM, Bennett V. 1993. The junctional complex of the membrane skeleton. Semin Hematol 30:74-83.
11. Gomez S, Morgans C. 1993. Interaction between band 3 and ankyrin begins in early compartments of the secretory pathway and is essential for band 3 processing. J Biol Chem 268:19593-19597.
12. Groves JD, Falson P, le Maire M, Tanner MJ. 1996. Functional cell surface expression of the anion transport domain of human red cell band 3 (AE1) in the yeast Saccharomyces cerevisiae. Proc Natl Acad Sci 93:12245-12250.
13. Hamasaki N, Okubo K, Kuma H, Kang D, Yae Y. 1997. Proteolytic cleavage sites of band 3 protein in alkali-treated membranes: Fidelity of hydropathy prediction for band 3 protein. J Biochem (Tokyo) 122:577-585.
14. Illsley NP, Verkman AS. 1987. Membrane chloride transport measured using a chloride-sensitive fluorescent probe. Biochemistry 26:1215-1219.
15. Jennings ML. 1989. Structure and function of the red blood cell anion transport protein. Annu Rev Biophys Biophys Chem 18:397-430.
16. Kopito RR, Lodish HF. 1985. Primary structure and transmembrane orientation of the murine anion exchange protein. Nature 316:234-238.
17. Korsgren C, Cohen CM. 1988. Associations of human erythrocyte band 4.2. binding to ankyrin and to the cytoplasmic domain of band 3. J Biol Chem 263:10212-102128.
18. - exchanger. J Biol Chem 265:462-471.
19. Li YP, Andersen J, Zelent A, Rao S, Paietta E, Tallman MS, Wiernik PH, Gallagher RE. 1997. RAR alpha1/RAR alpha2-PML mRNA expression in acute promyelocytic leukemia cells: A molecular and laboratory-clinical correlative study. Blood 90:306-312.
20. Low PS. 1986. Structure and function of the cytoplasmic domain of band 3: Center of erythrocyte membrane-peripheral protein interactions. Biochim Biophys Acta 22:145-167.
21. Mahieux R, Pise-Masison C, Gessain A, Brady JN, Olivier R, Perret E, Misteli T, Nicot C. 2001. Arsenic trioxide induces apoptosis in human T-cell leukemia virus type 1- and type 2-infected cells by a caspase-3-dependent mechanism involving Bcl-2 cleavage. Blood 98:3762-3769.
22. Miller Jr, WH, Schipper HM, Lee JS, Singer J, Waxman S. 2002. Mechanisms of action of arsenic trioxide. Cancer Res 62:3893-3903.
23. Porter AC, Fanger GR, Vaillancourt RR. 1999. Signal transduction pathways regulated by arsenate and arsenite. Oncogene 18:7794-7802.
24. Schieck E, Sanchez CP, Lanzer M. 2004. Targeting a DBL3 gamma domain of the Plasmodium falciparum erythrocyte membrane protein 1 to the surface of Saccharomyces cerevisiae. Parasitol Res 93:318-321.
25. Sekler I, Kopito R, Casey JR. 1995. High level expression, partial purification, and functional reconstitution of the human AE1 anion exchanger in Saccharomyces cerevisiae. J Biol Chem 270:21028-21034.
26. Shao W, Fanelli M, Ferrara FF, Riccioni R, Rosenauer A, Davison K, Lamph WW, Waxman S, Pelicci PG, Lo Coco F, et al. 1998. Arsenic trioxide as an inducer of apoptosis and loss of PML/RAR protein in acute promyelocytic leukemia cells. J Natl Cancer Inst 90:124-133.
27. 3) in the treatment of acute promyelocytic leukemia (APL): II. Clinical efficacy and pharmacokinetics in relapsed patients. Blood 89:3354-3360.
28. Sheng M, Sala C. 2001. PDZ domains and the organization of supramolecular complexes. Annu Rev Neurosci 24:1-29.
29. Soignet SL, Maslak P, Wang ZG, Jhanwar S, Calleja E, Dardashti LJ, Corso D, DeBlasio A, Gabrilove J, Scheinberg DA, et al. 1998. Complete remission after treatment of acute promyelocytic leukemia with arsenic trioxide. N Engl J Med 339:1341-1348.
30. Toye AM, Bruce LJ, Unwin RJ, Wrong O, Tanner MJ. 2002. Band 3 Walton, a C-terminal deletion associated with distal renal tubular acidosis, is expressed in the red cell membrane but retained internally in kidney cells. Blood 99:342-347.
31. Vince JW, Reithmeier RA. 2000. Identification of the carbonic anhydrase II binding site in the Cl(-)/HCO(3)(-) anion exchanger AE1. Biochemistry 39:5527-5533.
32. - exchanger are encoded by mRNAs transcribed from alternative promoters. J Biol Chem 271:7835-7843.
33. Wang TS, Shu YF, Liu YC, Jan KY, Huang H. 1997. Glutathione peroxidase and catalase modulate the genotoxicity of arsenite. Toxicology 121:229-237.
34. Waxman S, Anderson KC. 2001. History of the development of arsenic derivatives in cancer therapy. The Oncol. 6:S2-10.
35. Yannoukakos D, Meyer HE, Vasseur C, Driancourt C, Wajcman H, Bursaux E. 1991. Three regions of erythrocyte band 3 protein are phosphorylated on tyrosines: Characterization of the phosphorylation sites by solid phase sequencing combined with capillary electrophoresis. Biochim Biophys Acta 1066:70-76.
36. Yannoukakos D, Stuart-Tilley A, Fernandez HA, Fey P, Duyk G, Alper SL. 1994. Molecular cloning, expression, and chromosomal localization of two isoforms of the AE3 anion exchanger from human heart. Circ Res 75:603-614.
37. Zhang P, Wang S, Hu L, Shi F, Qiu F, Hong L, Han X, Yang H, Song Y, Liu Y, et al. 1996. Treatment of acute promyelocytic leukemia with intravenous arsenic trioxide. Chin J Hematol 17:58-62.
38. Zhang D, Kiyatkin A, Bolin JT, Low PS. 2000. Crystallographic structure and functional interpretation of the cytoplasmic domain of erythrocyte membrane band 3. Blood 96:2925-2933.
39. Zheng Y, Shi Y, Tian C, Jiang C, Jin H, Chen J, Almasan A, Tang H, Chen Q. 2004. Essential role of the voltage-dependent anion channel (VDAC) in mitochondrial permeability transition pore opening and cytochrome c release induced by arsenic trioxide. Oncogene 23:1239-1247.
40. 3-induced apoptosis in lymphoma cells: Involvement of hydrogen peroxide catabolism. Blood 105:1198-1203.
41. Zhu J, Koken MH, Quignon F, Chelbi-Alix MK, Degos L, Wang ZY, Chen Z, de The H. 1997. Arsenic-induced PML targeting onto nuclear bodies: Implications for the treatment of acute promyelocytic leukemia. Proc Natl Acad Sci 94:3978-3983.
42. Zhu J, Okumura H, Ohtake S, Nakamura S, Nakao S. 2003a. Arsenic trioxide induces apoptosis in leukemia/lymphoma cell lines via the CD95/CD95L system. Oncol Rep 3:705-709.
43. Zhu Q, Zhang JW, Zhu HQ, Shen YL, Flexor M, Jia PM, Yu Y, Cai X, Waxman S, Lanotte M, et al. 2003b. Synergic effects of arsenic trioxide and cAMP during acute promyelocytic leukemia cell maturation subtends a novel signaling cross-talk. Blood 99:1014-1022.